Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of ritlecitinib 50 mg vs 100 mg once daily in adolescents and adults with alopecia areata
CTR20252310Phase 3Active
- Sponsor
- Pfizer
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ritlecitinib tosilate in alopecia areata, sponsored by Pfizer. Started Jul 2025; status: active.
02
Drugs
ritlecitinib tosilate
03
Conditions
alopecia areata
Beyond the preview
Go deeper on CTR20252310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252310.